8-K Announcements
6Material company update
Mar 4, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Oct 27, 2025·SEC
Impact BioMedical Inc.(IBO)Earnings, Financials & Key Ratios
IBO•AMEX
$0.64
$148M mkt cap·Price updated May 6, 2026
AboutImpact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.Show more
- Revenue$2M
- EBITDA$895K+130.8%
- Net Income-$2M+52.7%
- EPS (Diluted)-0.01
- Gross Margin100%
- EBITDA Margin38.4%
- Operating Margin23.67%
- Net Margin-88.01%
- ROE-11.56%+18.8%
- ROIC1.52%+120.9%
- Debt/Equity1.23+187.1%
- Interest Coverage3.27+136.0%
IBO Key Insights
Impact BioMedical Inc. (IBO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 84 (top 16%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 21.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 27.7x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IBO Price & Volume
Impact BioMedical Inc. (IBO) stock price & volume — 10-year historical chart
Loading chart...
IBO Growth Metrics
Impact BioMedical Inc. (IBO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years259.91%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-460.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-901.33%
Return on Capital
10 Years-252.07%
5 Years-311.75%
3 Years-5.96%
Last Year2.63%
IBO Recent Earnings
Impact BioMedical Inc. (IBO) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
Mar 27, 2026EPS
$0.42
Revenue
$7,000
Q4 2025
Nov 7, 2025EPS
$0.12
Revenue
$18,000
Q3 2025
Aug 14, 2025EPS
$1.18
Revenue
$5,119
Q2 2025
May 14, 2025EPS
$0.11
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 27, 2026 | $0.42 | $7,000 |
| Q4 2025 | Nov 7, 2025 | $0.12 | $18,000 |
| Q3 2025 | Aug 14, 2025 | $1.18 | $5,119 |
| Q2 2025 | May 14, 2025 | $0.11 | — |
Based on last 6 quarters of dataView full earnings history →
IBO Peer Comparison
Impact BioMedical Inc. (IBO) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NNVC | 31.53M | 1.46 | -2.32 | -20.06% | ||||
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 VXRT | 179.17M | 0.75 | 10.64 | 7.27% | 6.88% | 33.83% | 0.10 | |
 OCGN | 492.54M | 1.46 | -6.33 | 8.83% | -15.37% | -26.26% | ||
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ICLR | 9.48B | 124.13 | 13.03 | 1.99% | 7.4% | 6.32% | 0.38 | |
 CRL | 8.97B | 181.73 | -62.45 | -0.85% | -3.59% | -4.34% | 0.95 |
Compare IBO vs Peers
Impact BioMedical Inc. (IBO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IBO Income Statement
Impact BioMedical Inc. (IBO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'18 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 50K | 50K | 0 | 2.33M | 0 |
| Revenue Growth % | - | - | - | - | - | 0% | -100% | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 564K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 50K▲ 0% | 50K▲ 0.0% | 0▼ 100.0% | 2.33M▲ 0% | -564K▲ 0% |
| Gross Margin % | - | - | - | - | 100% | 100% | - | 100% | - |
| Gross Profit Growth % | - | - | - | - | - | 0% | -100% | - | - |
| Operating Expenses | 176.23K | 68.85K | 680.02K | 1.14M | 3.45M | 3.45M | 4.03M | 1.78M | 28.43M |
| OpEx % of Revenue | - | - | - | - | 6908% | 6908% | - | 76.33% | - |
| Selling, General & Admin | 176.23K | 68.85K | 237.72K | 487.38K | 1.05M | 1.05M | 1.1M | 1.02M | 2.03M |
| SG&A % of Revenue | - | - | - | - | 2094% | 2094% | - | 43.65% | - |
| Research & Development | 0 | 0 | 442.3K | 653.63K | 1.23M | 1.23M | 1.69M | 91.77K | 198K |
| R&D % of Revenue | - | - | - | - | 2452% | 2452% | - | 3.94% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 1.18M | 1.18M | 1.24M | 670.05K | 1.45M |
| Operating Income | 63.95K▲ 0% | -33.86K▼ 152.9% | -680.02K▼ 1908.3% | -1.14M▼ 67.8% | -3.4M▼ 198.3% | -3.4M▲ 0.0% | -4.03M▼ 18.3% | 551.66K▲ 113.7% | -28.99M▲ 0% |
| Operating Margin % | - | - | - | - | -6808% | -6808% | - | 23.67% | - |
| Operating Income Growth % | - | -152.95% | -1908.28% | -67.79% | -198.33% | 0% | -18.33% | 113.7% | - |
| EBITDA | 225.09K | 138K | 0 | 0 | -2.29M | -2.29M | -2.91M | 895.13K | -27.87M |
| EBITDA Margin % | - | - | - | - | -4582% | -4582% | - | 38.4% | - |
| EBITDA Growth % | - | -38.69% | -100% | - | - | 0% | -26.93% | 130.78% | -869.12% |
| D&A (Non-Cash Add-back) | 161.14K | 171.86K | 680.02K | 1.14M | 1.11M | 1.11M | 1.12M | 343.46K | 1.12M |
| EBIT | 0 | 0 | -680.02K | -1.14M | -7.41M | -7.41M | -3.96M | -1.88M | -23.91M |
| Net Interest Income | 8.12K | 5.73K | 562 | 0 | -438K | -438K | -431K | -163.26K | -1.09M |
| Interest Income | 8.12K | 5.73K | 562 | 0 | 24K | 24K | 13K | 5.69K | 12K |
| Interest Expense | 0 | 0 | 0 | 0 | 462K | 462K | 444K | 168.95K | 1.11M |
| Other Income/Expense | -240.18K | -34.99K | -169.21K | 0 | -4.47M | -4.47M | -379K | -2.6M | 3.97M |
| Pretax Income | -408.29K▲ 0% | -98.11K▲ 76.0% | -849.24K▼ 765.6% | -1.14M▼ 34.4% | -7.88M▼ 590.3% | -7.88M▲ 0.0% | -4.41M▲ 44.0% | -2.05M▲ 53.4% | -25.02M▲ 0% |
| Pretax Margin % | - | - | - | - | -15752% | -15752% | - | -88.01% | - |
| Income Tax | 0 | 0 | 0 | -104.34K | -621K | -621K | 0 | 0 | 33K |
| Effective Tax Rate % | 0% | 0% | 0% | 9.14% | 7.88% | 7.88% | 0% | 0% | -0.13% |
| Net Income | -408.29K▲ 0% | -98.11K▲ 76.0% | -590.08K▼ 501.5% | -760.07K▼ 28.8% | -7.05M▼ 827.7% | -7.05M▲ 0.0% | -4.34M▲ 38.5% | -2.05M▲ 52.7% | -25.02M▲ 0% |
| Net Margin % | - | - | - | - | -14102% | -14102% | - | -88.01% | - |
| Net Income Growth % | - | 75.97% | -501.45% | -28.81% | -827.68% | 0% | 38.51% | 52.68% | -460.79% |
| Net Income (Continuing) | -408.29K | -98.11K | -849.24K | -1.04M | -7.25M | -7.25M | -4.41M | -2.05M | -25.05M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 3.31M | 3.11M | 3.04M | 2.98M | 2.97M |
| EPS (Diluted) | -0.04▲ 0% | -0.01▲ 75.0% | -0.01▲ 0.0% | -0.01▼ 8.0% | -0.61▼ 5548.1% | -0.61▲ 0.0% | -0.01▲ 98.4% | -0.01▲ 0.0% | -2.07▲ 0% |
| EPS Growth % | - | 75% | 0% | -8% | -5548.15% | 0% | 98.36% | 0% | -901.33% |
| EPS (Basic) | -0.04 | -0.01 | -0.01 | -0.01 | -0.61 | -0.61 | -0.01 | -0.01 | - |
| Diluted Shares Outstanding | 10.21M | 9.81M | 11.83M | 70.5K | 60.25M | 11.5M | 191.3M | 232.5M | 12.06M |
| Basic Shares Outstanding | 10.21M | 9.81M | 11.83M | 70.5K | 11.5M | 11.5M | 191.3M | 232.5M | 12.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IBO Balance Sheet
Impact BioMedical Inc. (IBO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'18 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 320.66K | 217.21K | 115.34K | 71.7K | 287K | 122K | 332K | 2.45M | 2.18M |
| Cash & Short-Term Investments | 51.92K | 204.93K | 97.67K | 52.14K | 46K | 2K | 1K | 2M | 1.32M |
| Cash Only | 51.92K | 204.93K | 97.67K | 52.14K | 46K | 2K | 1K | 2M | 1.32M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 28.62K | 4.38K | 35.19K | 14.06K | 197K | 16K | 331K | 184K | 204K |
| Days Sales Outstanding | - | - | - | - | 1.44K | 116.8 | - | 28.81 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 489K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | 79.12 |
| Other Current Assets | 0 | 0 | -17.52K | 0 | 1K | 43K | 0 | 0 | 172K |
| Total Non-Current Assets | 0 | 0 | 1.27K | 1.04K | 56.14M | 46.38M | 44.3M | 17.84M | 17.87M |
| Property, Plant & Equipment | 0 | 0 | 1.27K | 1.04K | 0 | 276K | 287K | 17K | 16K |
| Fixed Asset Turnover | - | - | - | - | - | 0.18x | - | 137.12x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 25.09M | 25.09M | 25.09M | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 21.15M | 20.03M | 18.92M | 17.81M | 17.85M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 4.82M | 782K | 0 | 17K | 143K |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 5.08M | 190K | 0 | 0 | 0 |
| Total Assets | 320.66K▲ 0% | 217.21K▼ 32.3% | 116.61K▼ 46.3% | 72.74K▼ 37.6% | 56.42M▲ 77466.5% | 46.5M▼ 17.6% | 44.63M▼ 4.0% | 20.29M▼ 54.5% | 20.05M▲ 0% |
| Asset Turnover | - | - | - | - | 0.00x | 0.00x | - | 0.11x | 0.00x |
| Asset Growth % | - | -32.26% | -46.31% | -37.62% | 77466.53% | -17.59% | -4.01% | -54.54% | 148361.34% |
| Total Current Liabilities | 25.44K | 20.09K | 21.72K | 18.03K | 12.64M | 10.59M | 13.14M | 9.79M | 9.97M |
| Accounts Payable | 0 | 0 | 0 | 0 | 115K | 539K | 832K | 713K | 615K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 536.34 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 12.52M | 9.99M | 12.07M | 8.88M | 9.14M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 21.72K | 18.03K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 12.61x | 10.81x | 5.31x | 3.98x | 0.02x | 0.01x | 0.03x | 0.25x | 0.25x |
| Quick Ratio | 12.61x | 10.81x | 5.31x | 3.98x | 0.02x | 0.01x | 0.03x | 0.25x | 0.25x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | -457.22 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 60K | 3.86M | 3.23M | 3.23M | 3.27M | 3.27M |
| Long-Term Debt | 0 | 0 | 0 | 60K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 3.86M | 3.23M | 3.23M | 3.27M | 13.01M |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 25.44K | 20.09K | 21.72K | 78.03K | 16.5M | 13.83M | 16.37M | 13.05M | 13.24M |
| Total Debt | 0 | 0 | 0 | 60K | 12.52M | 9.99M | 12.07M | 8.88M | 9.14M |
| Net Debt | -51.92K | -204.93K | -97.67K | 7.86K | 12.48M | 9.99M | 12.07M | 6.88M | 7.82M |
| Debt / Equity | - | - | - | - | 0.31x | 0.31x | 0.43x | 1.23x | 1.23x |
| Debt / EBITDA | - | - | - | - | - | - | - | 9.92x | -0.33x |
| Net Debt / EBITDA | -0.23x | -1.49x | - | - | - | - | - | 7.68x | 7.68x |
| Interest Coverage | - | - | - | - | -7.37x | -7.37x | -9.07x | 3.27x | -21.60x |
| Total Equity | 295.22K▲ 0% | 197.12K▼ 33.2% | 94.89K▼ 51.9% | -5.28K▼ 105.6% | 39.92M▲ 755807.0% | 32.67M▼ 18.2% | 28.26M▼ 13.5% | 7.24M▼ 74.4% | 6.81M▲ 0% |
| Equity Growth % | - | -33.23% | -51.86% | -105.57% | 755806.98% | -18.17% | -13.49% | -74.39% | 150017.67% |
| Book Value per Share | 0.03 | 0.02 | 0.01 | -0.07 | 0.66 | 2.84 | 0.15 | 0.03 | 0.56 |
| Total Shareholders' Equity | 295.22K | 197.12K | 94.89K | -5.28K | 36.61M | 29.56M | 25.22M | 4.26M | 3.84M |
| Common Stock | 595.51K | 595.51K | 619.1K | 696.75K | 125K | 70K | 10K | 11K | 12K |
| Retained Earnings | -408.29K | -506.4K | -624.71K | -831.93K | -1.57M | -8.63M | -12.96M | -37.67M | -38.94M |
| Treasury Stock | - | - | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 3.31M | 3.11M | 3.04M | 2.98M | 2.97M |
IBO Cash Flow Statement
Impact BioMedical Inc. (IBO) cash flow — operating, investing & free cash flow history
| Line item | Mar'18 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -320.34K | -71.99K | -121.98K | -1.14K | -3.25M | -4.33M | -2.85M | -3.92M | -3.92M |
| Operating CF Margin % | - | - | - | - | -6499.46% | -8666.33% | - | -168.12% | - |
| Operating CF Growth % | - | 77.53% | -69.44% | 99.06% | -284215.75% | -33.34% | 34.21% | -37.46% | -233220.06% |
| Net Income | -408.29K | -98.11K | -118.31K | -760 | -3.87M | -10.5M | -4.41M | -24.77M | -25.02M |
| Depreciation & Amortization | 0 | 0 | 255 | 0 | 69.86K | 266.4K | 1.12M | 1.12M | 839.41K |
| Stock-Based Compensation | 94K | 0 | 0 | 0 | 0 | 903.54K | 0 | 19K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 2.71M | 0 | 33K | 0 |
| Other Non-Cash Items | 0 | 0 | 0 | -377 | 829.56K | 2.79M | 0 | 20.29M | 20.11M |
| Working Capital Changes | -6.05K | 26.12K | -3.93K | -5 | -281.93K | -507.7K | 436K | -608K | -613.84K |
| Change in Receivables | -27.77K | 24.24K | -5.81K | 0 | 0 | 0 | -128K | 128K | 128K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 279.91K | -474.4K | 293K | -436K | -627K |
| Cash from Investing | -225K | 225K | -26.53K | -804 | -42.93K | -2.09M | -15K | 2K | 2K |
| Capital Expenditures | 0 | 0 | -1.53K | 0 | 0 | -95.68K | -18K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | 552% | 191.36% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -2.05M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -225K | 225K | -25K | -804 | -42.93K | 54.78K | 3K | 2K | 2K |
| Cash from Financing | 209.51K | 0 | 16.09K | 1.9K | 3.38M | 7.01M | 2.87M | 5.92M | 5.43M |
| Debt Issued (Net) | - | - | 0 | 0 | 2.55M | 2.55M | 2.87M | 2.19M | 1.71M |
| Equity Issued (Net) | - | - | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | -410K | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -46.45K | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 16.09K | 1.9K | 1.25M | 4.46M | 0 | 0 | 0 |
| Net Change in Cash | -335.83K▲ 0% | 153.01K▲ 145.6% | -132.43K▼ 186.6% | 43▲ 100.0% | 89.61K▲ 208307.0% | 583.85K▲ 551.5% | -1K▼ 100.2% | 2M▲ 199900.0% | 2M▲ 0% |
| Free Cash Flow | -320.34K▲ 0% | -71.99K▲ 77.5% | -123.51K▼ 71.6% | -1.14K▲ 99.1% | -3.25M▼ 284215.7% | -4.43M▼ 36.3% | -2.87M▲ 35.2% | -3.92M▼ 36.6% | -3.44M▲ 0% |
| FCF Margin % | - | - | - | - | -6499.46% | -8857.69% | - | -168.12% | - |
| FCF Growth % | - | 77.53% | -71.56% | 99.07% | -284215.75% | -36.28% | 35.22% | -36.6% | -274.96% |
| FCF per Share | -0.03 | -0.01 | -0.01 | -0.02 | -0.05 | -0.39 | -0.01 | -0.02 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.73x | 0.21x | 0.00x | 0.46x | 0.61x | 0.66x | 1.91x | 0.14x |
| Interest Paid | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IBO Key Ratios
Impact BioMedical Inc. (IBO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.85% | -404.16% | -1696.43% | -35.33% | -19.43% | -14.23% | -11.56% | -367.36% |
| Return on Invested Capital (ROIC) | -21.57% | - | -33156.13% | -9.74% | -5.37% | -7.28% | 1.52% | 1.52% |
| Gross Margin | - | - | - | 100% | 100% | - | 100% | - |
| Net Margin | - | - | - | -14102% | -14102% | - | -88.01% | - |
| Debt / Equity | - | - | - | 0.31x | 0.31x | 0.43x | 1.23x | 1.23x |
| Interest Coverage | - | - | - | -7.37x | -7.37x | -9.07x | 3.27x | -21.60x |
| FCF Conversion | 0.73x | 0.21x | 0.00x | 0.46x | 0.61x | 0.66x | 1.91x | 0.14x |
| Revenue Growth | - | - | - | - | 0% | -100% | - | - |
IBO SEC Filings & Documents
Impact BioMedical Inc. (IBO) SEC filings — annual & quarterly reports (10-K, 10-Q)
IBO Frequently Asked Questions
Impact BioMedical Inc. (IBO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Impact BioMedical Inc. (IBO) reported $2.3M in revenue for fiscal year 2024.
Impact BioMedical Inc. (IBO) grew revenue by 0.0% over the past year. Growth has been modest.
Impact BioMedical Inc. (IBO) reported a net loss of $25.0M for fiscal year 2024.
Dividend & Returns
Impact BioMedical Inc. (IBO) has a return on equity (ROE) of -11.6%. Negative ROE indicates the company is unprofitable.
Impact BioMedical Inc. (IBO) had negative free cash flow of $3.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More IBO
Impact BioMedical Inc. (IBO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates